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Abstract 
 
Background: The H69CIS200 and H69OX400 cell lines are novel models of low-
level platinum-drug resistance. Resistance was not associated with increased cellular 
glutathione or decreased accumulation of platinum, rather the resistant cell lines have 
a cell cycle alteration allowing them to rapidly proliferate post drug treatment. 
Results: A decrease in ERCC1 protein expression and an increase in RAD51B foci 
activity was observed in association with the platinum induced cell cycle arrest but 
these changes did not correlate with resistance or altered DNA repair capacity. The 
H69 cells and resistant cell lines have a p53 mutation and consequently decrease 
expression of p21 in response to platinum drug treatment, promoting progression of 
the cell cycle instead of increasing p21 to maintain the arrest.  
Conclusion: Decreased ERCC1 protein and increased RAD51B foci may in part be 
mediating the maintenance of the cell cycle arrest in the sensitive cells. Resistance in 
the H69CIS200 and H69OX400 cells may therefore involve the regulation of ERCC1 
and RAD51B independent of their roles in DNA repair. The novel mechanism of 
platinum resistance in the H69CIS200 and H69OX400 cells demonstrates the 
multifactorial nature of platinum resistance which can occur independently of 
alterations in DNA repair capacity and changes in ERCC1. 
 
Keywords: Cisplatin, Oxaliplatin, Resistance, Cell Cycle, DNA Repair, ERCC1, 
RAD51B, p21, Small Cell Lung Cancer 
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Introduction 
 
The chemotherapeutic drugs cisplatin and oxaliplatin cause cytotoxicity by covalently 
binding to DNA forming adducts which hinder both RNA transcription and DNA 
replication. DNA damage normally causes a coordinated cellular response which 
involves arrest of the cell cycle to accommodate DNA repair, followed either by 
resumption of the cell cycle or apoptosis depending on the success or failure of the 
DNA repair process respectively. This coordinated response protects against 
mutations and therefore maintains genomic stability. 
 
The H69CIS200 cisplatin-resistant and H69OX400 oxaliplatin-resistant small cell 
lung cancer cell lines are novel models of low-level platinum resistance [1]. The 
H69CIS200 and H69OX400 cell lines were developed from parental H69 small cell 
lung cancer cells with eight 4-day treatments of 200 ng/ml cisplatin or 400 ng/ml 
oxaliplatin respectively. These cell lines are approximately 2-fold resistant to cisplatin 
and oxaliplatin and are cross resistant to both drugs. The resistance is not associated 
with increased cellular glutathione or decreased accumulation of platinum which are 
common mechanisms of platinum resistance. The H69 platinum sensitive cells enter a 
lengthy 3 week growth arrest in response to low-level cisplatin and oxaliplatin 
treatment. This is an example of the coordinated response between the cell cycle and 
DNA repair. In contrast the H69CIS200 and H69OX400 cells have an alteration in the 
cell cycle allowing them to rapidly proliferate post drug treatment. The resistant cell 
lines also have many chromosomal rearrangements most of which are not associated 
with the resistant phenotype, suggesting an increase in genomic instability in the 
resistant cell lines [2]. We hypothesised that there was a deregulation between the cell 
cycle and DNA repair in the resistant cell lines allowing proliferation in the presence 
of DNA damage which has created an increase in genomic instability. Here we 
investigate the DNA repair processes involved in this deregulation and their role in 
permitting cell cycle progression in the platinum-resistant cell lines. 
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Methods 
 
Cell Culture 
 
The human H69 small cell lung cancer cell line was obtained from the American Type 
Culture Collection (Virginia, USA). The H69CIS200 and H69OX400 cells were 
developed over 8 months with eight 4-day treatments of 200 ng/ml cisplatin and 400 
ng/ml oxaliplatin respectively [1]. There was no change in growth rate or morphology 
associated with the resistance. All cells and sublines were maintained in drug and 
antibiotic-free RPMI (Thermoelectron, Sydney, Australia) with 10% FCS in a 
humidified atmosphere with 5% CO2 at 37°C. The cultures were tested regularly and 
were mycoplasma free. Flow cytometry cell cycle analysis and MTT cytotoxicity 
assays were performed as previously described [1].  
 
Real-Time PCR 
 
Total RNA was extracted and purified for real-time PCR using the Atlas pure total 
RNA labelling system (BD Biosciences). 2 µg total RNA was converted to cDNA 
using Bioscript RNase H Minus (Bioline, Sydney, Australia). Primers were designed 
with Primer 3 [3] with the following parameters, optimum Tm of 60°C, and optimum 
amplicon length of 120 bases and are presented in Table 1. Primers were Guaranteed 
Oligos
TM
 synthesised by Sigma-Proligo (Lismore, New South Wales, Australia). The 
general 25 µl reaction mix for real-time PCR was as follows:- 12.5 µl 2X Immomix 
(Bioline), 0.75 µl Forward primer 10 µM, 0.75 µl Reverse primer 10 µM, 1.2 µl Sybr-
Green 10X stock (Invitrogen, Melbourne, Australia), 1 µl cDNA and 8.8 µl sterile 
H2O. The real-time PCR reaction was carried out on a Rotor Gene real-time PCR 
machine (Corbett Research, Sydney, Australia).  FAM-Sybr Green was detected 
during the 72°C extension step of each cycle and a melt curve was performed at the 
end of the run to confirm the amplification of a single product. The cycling conditions 
were as follows:- Step 1 - 95°C 10 minutes, Step 2 - 95°C 20 seconds, 60°C 20 
seconds, 72°C 20 seconds (40 cycles). The real-time PCR reactions were analysed 
with Rotor Gene 6 software (Corbett Research). A β-actin standard curve using H69 
control cDNA serially diluted from 1:10 to 1:10000 was performed in each  
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real-time PCR run. The reaction rate of each primer set was the same as the β-actin 
primer set. A Ct value was calculated by Rotor Gene 6 for each unknown sample and 
standard and relative expression of each unknown sample was interpolated from the 
β-actin standard curve in each run.  
 
Western Blotting 
 
Cells were washed in cold PBS (0.15M NaCl, 0.03M NaH2PO4, 0.07M Na2HPO4 , pH 
7.2), and resuspended in 100µl of lysis buffer (0.01M Tris/HCl, pH 7.4) at 4°C. 10µl 
complete protease inhibitor (Roche, Sydney, Australia) was added prior to 
sonnication. 20 µg protein was then electrophoresed and Western blotted as 
previously described [4], with the following modifications. A 12% acrylamide 
Tris/glycine gels with a 4% stacking gel was used and Biorad broad range markers 
were used as indicated (Biorad, Sydney, Australia). The blots were then stained with 
ponceau-s-red solution (Sigma, Sydney, Australia) to check the protein had 
transferred properly and to enable quantitation of loading in each lane. The primary 
antibodies and dilutions used were ERCC1 1:200 (ERCC1 Ab-1(3H11) mAb from 
Labvision via DKSH, Melbourne, Australia), RAD51B 1:1000 (RAD51B Antibody 
[1H3/13] from Abcam via Sapphire Biosciences, Sydney, Australia), p21 1:1000 
(p21
WAF1
 Ab-11 (Clone CP74) from Labvision via DKSH, Melbourne, Australia) and 
phospho-H2AX(Ser 139) (Cell Signalling Technology via Genesearch, Brisbane, 
Australia). The secondary antibody was alkaline phosphatase (Chemicon, Melbourne, 
Australia) or HRP conjugated (Santa Cruz Biotechnology via Monarch Medical, 
Brisbane, Australia) mouse immunoglobin diluted 1: 500. 
 
RAD51B Immunocytochemistry 
 
1.25 x 10
5
 cells in 100 µl PBS were cytospun onto Superfrost® Plus slides (Menzel-
Glasier via Lomb Scientific, Sydney, Australia.) using reusable Shandon cytospin 
funnels and disposable filter cards (Thermoscientific, Melbourne, Australia). The 
slides were air dried and cells were then fixed by incubating the slides in 100% ice 
cold methanol for 5 minutes. The slides were air dried and stored at –20°C prior to 
analysis. The slides were incubated with a serum free protein block (Dako, Sydney, 
Australia.) for 10 minutes at room temperature in a humidified atmosphere. All 
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further incubations were also at room temperature in a humidified atmosphere. The 
blocking solution was tapped off and a 1: 100 dilution of RAD51B primary antibody 
(Abcam clone 1H3/13) was added in antibody diluent (Dako) and incubated for 2 
hours. The slides were then washed in D-PBS for 5 minutes. A 1: 300 dilution of 
FITC conjugated anti-mouse secondary antibody in antibody diluent was then added 
and incubated for 1 hour in the dark. The slides were then washed in D-PBS for 5 
minutes. Slides were incubated with a DAPI counterstain (1: 50 of 5 mg/ml stock 
solution in D-PBS) for 5 minutes in the dark and then again washed in D-PBS for 5 
minutes. Slides were air dried and then coverslipped using PermaFlour
TM
 Aqueous 
Mounting Medium (Thermoelectron). Slides were photographed at x 60 magnification 
using a Nikon Eclipse 80i Microscope. Two photographs were taken of each region of 
interest, one FITC image for the stained primary antibody of interest and one DAPI 
image for the nuclei. 
 
Platinated Plasmid DNA Repair Assay 
 
DNA repair was examined using a platinated β-galactosidase reporter plasmid 
transfected into cells and then β-galactosidase activity was detected in cell lysates 
using an enzymatic assay. Similar assays have been used in the literature using 
platinated luciferase [5] and Xgal [6] reporter plasmids. The pEF-Bos-β-galactosidase 
plasmid (a gift from Cancer Genetics, Kolling Institute, Royal North Shore Hospital) 
was purified from JM109 cells grown in Luria broth in the presence of 0.1 mg/ml 
ampicillin, using a Qiagen (Melbourne, Australia) Endofree Plasmid Maxi Kit 
according to the manufacturers instructions. The purified plasmids (0.1 mg/ml in TE 
buffer) were incubated in the dark at 37°C with different concentrations of cisplatin. 
The reaction was stopped by adding NaCl to a final concentration of 0.5M. Plasmid 
DNA was precipitated with 2 volumes of 100% ethanol at –70°C in the presence of 
2.5M ammonium acetate, washed in 70% ethanol, dried and dissolved in TE buffer. 
 
3.25 x 10
5
 H69, H69CIS200 or H69OX400 cells were resuspended in 400 µl RPMI 
with serum in a 24 well plate. All transfections were performed in triplicate. 0.2µg 
plasmid DNA (Control, 1% or 2% platinated) was diluted in 25 µl Qiagen Buffer EC 
then 1.6 µl Qiagen Enhancer was added and vortexed for 1 second and incubated for 5 
 7 
minutes at room temperature. 10 µl Qiagen Effectene transfection reagent was then 
added and incubated for 10 minutes at room temperature. 225 µl RPMI with serum 
and antibiotics was then added to the transfection mix which was then added dropwise 
to the cells. Cells were harvested for the β-galactosidase assay at 24 hours after 
transfection. 
 
Transfected H69 cells were sonnicated for 20 pulses in 100 µl 1X Reporter Assay 
Lysis Buffer (Promega, Sydney Australia). 40µl of lysate was added in duplicate to a 
96 well plate, 150µl of Assay Buffer (8.8 ml Phosphate Buffer (0.618g Na2HPO4 
anhydrous salt, 0.623g NaH2PO4.2H2O adjusted to pH 7.3 made up to 100ml with 
deionised H2O and frozen in aliquots at –20°C), 900 µl 100 mM MgCl2 and 70 µl 
Mercaptoethanol made fresh for each assay.) and 50µl of CPRG (1.5 mg/ml, Roche 
Applied Sciences, Sydney, Australia) was added to each well. The plate was then 
incubated at 37°C for 6 hours until an orange coloured product was seen. 
Absorbencies were then read at 595 nm. 
  
Analysis and Statistics 
 
Changes in mRNA and protein expression were determined relative to the untreated 
H69 control. Means and standard deviations are presented in the figures. Significant 
differences from the H69 control were determined on the raw data using a two tailed 
student’s t-test assuming the samples were of equal variance. 
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Results 
 
Growth and Cell Cycle Characteristics of the Platinum Resistant Cell Lines 
 
There was no change in growth rate of the H69CIS200 and H69OX400 resistant cell 
lines compared to the parental H69 cell line (Fig. 1). Fig. 1 also shows the cell 
viability of the H69, H69CIS200 and H69OX400 cells after a 4-day 200 ng/ml 
cisplatin or 400 ng/ml oxaliplatin drug treatment, the same doses of drug and length of 
treatment used in development of the resistant cell lines. All cell lines show decreased 
growth with treatment. However, the two resistant cell lines have significant growth 
advantage over the parental cells in response to both agents (p < 0.01 t-test).  
 
The cell cycle profile of each cell line at the end of the 4-day platinum drug 
treatments better demonstrates the difference between the sensitive and resistant cells. 
Fig. 2A shows the cell cycle profiles of the untreated sensitive and resistant cells were 
all the same and typical of cells in log-phase growth. After 4 days of treatment with 
cisplatin or oxaliplatin, the H69 sensitive cells were in a G2M arrest with increased 
numbers in sub-G0 and G2M, decreased numbers in G1 and no change in S phase (Fig. 
2B). The cisplatin treated H69CIS200 cells were also arrested showing similar but not 
as extensive cell cycle changes as the H69 cells (Fig. 2B) while in contrast, the 
H69OX400 cells did not arrest following oxaliplatin treatment but showed a profile 
similar to log-phase growth (Fig. 2C). The major difference between the resistant and 
sensitive cell lines is their rate of growth recovery post platinum drug treatment. Fig. 
2D shows the effect of treatment on the time to double cell numbers. The dotted line 
at 4 days indicates the timepoint where drug was removed. For the treated H69 cells 
the arrest lasted for 3 weeks compared to the oxaliplatin-treated H69OX400 cells that 
doubled in 5 days (p < 0.001 t-test) and the cisplatin-treated H69CIS200 cells showed 
an intermediate recovery time of 10 days (p < 0.05 t-test). 
 
The ability of cells to enter a protective cell cycle arrest and then proliferate later is 
known as regrowth resistance [1,7]. This kind of resistance is likely to be 
underestimated by short term growth curves and toxicity assays. The resistant cells 
have a greater potential for growth recovery after the toxic agent is removed as can be 
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seen from the cell cycle profile of the H69OX400 cells in Fig. 2C and the time to 
doubling data in Fig. 2D. 
 
p21 
 
p21
WAF1/CIP1
 inhibits cell cycle progression at the G1/S checkpoint by binding to and 
inhibiting the S-phase promoting Cdk2-CyclinE and Cdk4-CyclinD complexes [8]. 
We examined the protein expression of p21 by Western blot at the end of the four day 
platinum drug treatment (Fig. 3A and B). p21 appeared as two distinct bands the 
upper is the phosphorylated form of the protein [9]. The expression of the upper band 
significantly decreases in response to platinum drug treatment in the H69 cells relative 
to untreated cells (Fig. 3A). The upper band was also decreased in both untreated 
resistant cell lines. The expression of the lower p21 band shows less variability, 
however it was significantly decreased in the untreated H69OX400 cells compared to 
the H69 control (Fig. 3B). This decrease in the lower p21 band in the H69OX400 cells 
was partially reversed by platinum drug treatment but not fully to the level of 
untreated H69 cells. 
 
DNA Repair 
 
ERCC1 
 
ERCC1 is involved in the nucleotide excision repair removal of platinum adducts 
cutting on the 5’ side of the damaged DNA to be excised and replaced. ERCC1 is one 
of many rate limiting proteins involved in the damage recognition and excision 
process [10].  Increases in the expression of ERCC1 have been previously shown in 
response to cisplatin treatment and in cisplatin resistant cell models [10]. In contrast, 
we observed decreases in ERCC1 mRNA and protein expression (Fig. 4A and B). The 
decreases in ERCC1 protein expression were associated with the formation of a lower 
molecular weight band of approximately 26 kDa (marked with arrow Fig. 4B). We 
believe this to be the alternative spliced variant of ERCC1 which is missing exon 8 
and has been associated with decreased repair activity [11]. When the changes in 
ERCC1 mRNA and protein expression were analysed in reference to the cell cycle 
(Fig. 4C and D), the samples in cell cycle arrest (grey background) had a significant 
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decrease in mRNA and protein expression compared to the untreated control cells. 
This suggests that ERCC1 expression is more related to the cell cycle state of all cell 
lines than the resistant phenotype. The samples in cell cycle recovery were not 
significantly different from the untreated control cells but had lower levels of mRNA 
and protein suggesting that part of restoring normal cell cycle activity was associated 
with restoring normal ERCC1 levels. 
  
RAD51B  
 
Homologous recombination repair is in part mediated by the RAD51 proteins [8]. A 
downregulation of RAD51-mediated homologous recombination repair in knockout 
chicken B lymphocyte DT40 cells resulted in sensitivity to cisplatin treatment 
[12,13,14]. Therefore an increase in homologous recombination could mediate 
platinum resistance by increasing the repair of platinum induced double-strand DNA 
breaks. We chose to examine RAD51B as it has been linked to cell cycle control as 
well as DNA repair [15]. We observed some increases in RAD51B mRNA (Fig. 5A) 
but no change in protein expression (data not shown). In response to DNA damage 
RAD51 becomes concentrated in multiple discrete foci. These are thought to represent 
nuclear domains for homologous recombination repair [16]. The morphology of 
RAD51 can therefore indicate if it is actively repairing DNA. RAD51B foci were 
examined by immunocytochemistry in the H69, H69CIS200 and H69OX400 cell lines 
(Fig. 5B). The number of cells positive for RAD51B foci was counted for 6 fields of 
view under the microscope, analysing in total around 400 cells per slide.  Cells were 
deemed positive for RAD51B foci if they had greater than 5 foci in their nuclei, this 
criteria has been used in other RAD51 studies [17]. The parental H69 cells had higher 
levels of RAD51B foci in response to oxaliplatin drug treatment than the H69OX400 
cells (Fig. 5C). This is the opposite of what would be expected, since the resistant 
cells would be expected to have a higher level of repair than the sensitive parental 
cells. 
 
When the changes in RAD51B mRNA and foci were analysed in reference to the cell 
cycle state of the sample a pattern emerges (Fig. 5D and E). Both the RAD51B 
mRNA and activity were increased significantly in the arrested cells compared to the 
non-arrested controls, suggesting that its expression and activity are related more to 
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the cell cycle than to platinum resistance. The samples in cell cycle recovery had no 
change in RAD51B foci from the untreated cells suggesting that part of restoring 
normal cell cycle activity was restoring normal RAD51B foci activity. 
 
DNA Repair Activity  
 
The analysis of in vitro DNA repair activity is a compromise at best; some studies 
determine activity from whole cell extracts or nuclear extracts which may not 
accurately reflect repair in intact live cells. We have chosen two methods of 
determining DNA repair activity in intact cells, the phosphorylation of γH2AX and 
the repair of a transfected platinated plasmid. The expression of phospho-γH2AX is a 
marker of the early steps of DNA repair, particularly that of homologous 
recombination of double strand breaks. Phospho-γH2AX is a marker of the detection 
of these double strand breaks by the cell [18] and not necessarily successful DNA 
repair. However, cell lines with repair defects have been found to be deficient in 
phospho-γH2AX [19]. The repair of platinated reporter plasmids best corresponds to 
nucleotide excision repair, however the transfected plasmid is likely to be in the 
cytoplasm of the cell rather than the nucleus. Resistant cells with increases in DNA 
repair [5] or defects in DNA repair [6] have been detected by this method. By using 
these two methods we have examined the DNA repair pathways in which ERCC1 and 
RAD51B participate.  
 
Phospho-γH2AX was examined by Western blot in H69, H69CIS200 and H69OX400 
cells which had been drug treated for 4 days with either 200 ng/ml cisplatin or 400 
ng/ml oxaliplatin. However, phospho-γH2AX was undetectable at this time point 
(data not shown). The phosphorylation of γH2AX is an early event in DNA damage 
detection and repair [18], therefore H69, H69CIS200 and H69OX400 cells were 
treated with 200 ng/ml or 5 µg/ml cisplatin for 24 hours and examined for γH2AX 
phosphorylation by Western blot (Fig. 6A and B). Cisplatin treatment at 200 ng/ml 
induced the same amount of γH2AX phosphorylation in all cells. Cisplatin treatment 
at 5 µg/ml induced a higher amount of γH2AX phosphorylation in the resistant cell 
lines but this result was more variable and was not statistically significant. The higher 
dose of 5 µg/ml cisplatin is also above the clinically relevant doses used in the rest of 
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this study. These results suggest that there was no difference in the detection of DNA 
damage between the sensitive and resistant cell lines as measured by phospho-
γH2AX. 
 
β-galactosidase plasmids were platinated with cisplatin at two different doses, 
designed to place adducts on 1% and 2% of bases within the plasmid. These were then 
transfected into the H69, H69CIS200 and H69OX400 cells and β-galactosidase 
activity compared to an unplatinated control plasmid. β-galactosidase activity was 
measured at 24 hours post transfection, this time point allowed sufficient time for β-
galactosidase to be expressed in all samples. Fig. 6C shows that there was no increase 
in DNA repair of the platinated plasmids in the resistant cell lines compared to the 
parental sensitive cells. There was a small decrease in DNA repair in the H69OX400 
cells, however due to slight differences in transfection efficiency between cell lines 
this was not statistically significant. These results suggest that there is no difference in 
DNA repair between the sensitive and resistant cell lines as measured by the repair of 
platinated plasmids. 
 
The H69, H69CIS200 and H69OX400 cells were examined for their response to 
ionising radiation as cells with increased DNA repair capacity are often radiation 
resistant. The H69CIS200 cells are not radiation resistant as measured by this 5-day 
MTT assay (Fig. 6D). The H69OX400 cells were 2.68 fold resistant to radiation 
compared to the parental cells (p < 0.05 t-test). 
 
Discussion 
 
The H69 parental cells enter a lengthy three week growth arrest in response to 
cisplatin or oxaliplatin drug treatment (Fig. 2D). Resistance in the H69CIS200 and 
H69OX400 cells is associated with a more rapid recovery from this growth arrest. 
Increased expression of p21 causes the cell to arrest at the G1S checkpoint of the cell 
cycle [8], and has also been found to enhance the cytotoxic effect of cisplatin [20,21]. 
Therefore a decrease in the expression of p21 as observed in response to platinum 
treatment in both the sensitive H69 cells and in the resistant cell lines (Fig. 3) could 
promote platinum resistance by reducing the cytotoxic effect of the drug and enabling 
the cell to progress through the cell cycle. The H69 cells have a mutation in p53 [22]. 
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Decreasing the expression of p21 or no induction is a known response of mutant p53 
cells to cisplatin [23] or oxaliplatin treatment [24]. Therefore it is unlikely that p21 is 
causing the platinum induced cell cycle arrest in the H69 cells. The H69 cells and 
resistant cell lines also have an amplification of the c-myc gene on chromosome 8 [2] 
which would increase their ability to cycle after DNA damage [25] However, there 
was no increase in this amplification in the resistant cell lines compared to the 
sensitive parental cell line [2]. 
 
A similar pattern of growth arrest and recovery was observed in the development of 
cisplatin-resistant IGROV1 ovarian carcinoma cells [26] as in the H69CIS200 and 
H69OX400 cell lines. Development of resistance to cisplatin in IGROV1 cells was 
also associated with the ability of the treated cells to progress through the cell cycle 
beyond the G1/S checkpoint [26]. We have characterised this type of resistance as 
“regrowth resistance” where the cells arrest and then rapidly proliferate in response to 
a previously cytotoxic dose of drug [1]. This type of resistance is not related to the 
p53 status of the cell as the IGROV1 cells are wild-type p53 and increase p21 
expression in response to cisplatin drug treatment. The similarity of phenotype is 
rather linked to the low, clinically relevant dose of drug used in development and the 
pulsed selection strategy where the cells are allowed to recover in drug free media 
between treatments. 
 
No change in DNA repair capacity associated with platinum resistance 
 
Although increased nucleotide excision repair can cause cisplatin resistance [10] it 
appears not to be responsible for the platinum resistance of the H69CIS200 and 
H69OX400 cell lines as these cells showed no increases in ERCC1 mRNA or protein 
expression (Fig. 4A and B) and no increase in repair in the platinated repair assay 
(Fig. 6C). An increase in homologous recombination is also not responsible for the 
platinum resistance as there was no increase in RAD51B expression or nuclear foci 
formation (Fig. 5) nor was the level of phospho-γH2AX increased in the resistant 
relative to the sensitive H69 cell line (Fig. 6A).   
 
A decrease in mismatch repair has also been previously associated with cisplatin 
resistance, as the binding of the mismatch repair complex to Pt–DNA adducts appears 
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to increase the cytotoxicity of the adducts, either by activating apoptosis or by causing 
“futile cycling” during trans-lesion synthesis past Pt–DNA adducts [27]. Mismatch 
repair protein MSH2 was examined by Western blot and real time PCR and found not 
to have changed in the resistant cell lines (data not shown). The activity of oxaliplatin 
in some cisplatin-resistant cell lines is thought to be due to repair or damage 
recognition processes that discriminate between cisplatin and oxaliplatin adducts. This 
has been best established for mismatch repair, defects in mismatch repair increase 
resistance to cisplatin adducts, but have no effect on oxaliplatin adducts [27]. The 
H69CIS200 and H69OX400 cells are cross resistant to both cisplatin and oxaliplatin, 
this combined with no decrease of MSH2 suggests that there is no loss of mismatch 
repair mediating resistance to platinum.  
 
The resistance of the H69CIS200 and H69OX400 cells is therefore unlikely to be the 
result of changes in the DNA repair pathways which have been previously associated 
with platinum resistance. This highlights the multifactorial nature of platinum 
resistance and therefore the difficulty in using DNA repair proteins as markers of 
platinum resistance in the clinic. Some trials have found an association between 
ERCC1 and response to cisplatin combination therapy [28-30], but many more have 
found no association [31-35]. High ERCC1 may correlate with platinum resistance, 
but low or absent ERCC1 may not always indicate sensitivity as the H69CIS200 and 
H69OX400 when actively dividing show no change in ERCC1 despite being platinum 
resistant. 
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Changes in ERCC1 and RAD51B are associated with cell cycle arrest 
 
The changes in the DNA repair pathways are associated with the platinum induced 
cell cycle arrest rather than the resistant phenotype. There was a significant decrease 
in ERCC1 mRNA and protein expression (Fig. 4C and D) and increased RAD51B 
foci formation (Fig. 5E) associated with the samples in cell cycle arrest. The samples 
in cell cycle recovery have the same levels of expression of ERCC1 and RAD51B 
foci as untreated cells. This suggests that these DNA repair proteins are being 
modulated for reasons other than DNA repair and are potentially participating in the 
regrowth resistance mechanism of cell cycle arrest and recovery. 
  
There is some evidence to suggest that ERCC1 and RAD51B could mediate a cell 
cycle arrest. Hepatocytes from ERCC1 knockout mice are arrested in the G2 phase of 
the cell cycle [36]. The H69 cells enter a G2 arrest in response to platinum drug 
treatment (Fig. 2) associated with a decrease in ERCC1 expression (Fig. 4). The 
expression of full length ERCC1 decreases in association with the cell cycle arrest, 
however this is associated with the formation of an ERCC1 splice variant which has 
been previously reported to have reduced DNA repair activity [11]. It is possible that 
this splice variant may have an increased role in the process of cell cycle arrest.   
Fibroblasts from ERCC1 knockout mice also show a decreased rate of cell growth and 
disruptions in cell cycle [37] suggesting that the decrease in ERCC1 may contribute to 
the lengthy growth arrest in the sensitive cells. 
 
Transfection of RAD51B into CHO cells induces a cell cycle G1 delay similar to what 
was observed in the H69 cells in response to platinum treatment [38]. The cell cycle 
arrest in both cases appears as a flattening of the G1 peak. Transfection of RAD51 into 
human and rat fibroblasts also induces a G1 arrest [16].  
 
Confirmation of Mechanism of Cell Cycle Arrest by Transfection or RNAi ? 
 
The next logical step in many research studies of this kind would be to increase the 
expression of RAD51B by transfection and/or decrease the expression of ERCC1 by 
RNAi or other methods. However, we believe that these experiments would not 
conclusively prove the mechanism of regrowth resistance which we have proposed. 
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The changes we have found are transient and associated with cell cycle arrest after 
platinum treatment, not permanent changes in the resistant cell lines. The resistance 
produced in this model is low level, and as such is likely to be comprised of many 
small changes of which we have only identified two in this study. Replicating this 
mechanism by altering the expression of two genes is very unlikely. 
 
Increasing the expression of RAD51B would most likely lead to an increase in 
platinum resistance due to an increase in homologous recombination based DNA 
repair. This model shows no increase in DNA repair as the increase in RAD51B is 
transient during the cell cycle arrest. Decreasing the expression of ERCC1 would 
most likely lead to platinum sensitivity due to a downregulation of nucleotide excision 
repair as it did in response to ERCC1 siRNA in HeLa S3, MCF-7 and HCT116 cells 
in a recent study [39]. Again this is not a change observed in this model, and the 
alteration of ERCC1 may be post-translational modification of the protein rather than 
a decrease in expression. 
 
Platinum Resistance and Checkpoint Adaptation 
 
The H69CIS200 and H69OX400 cells do not use any of the well characterised 
mechanisms of platinum resistance such as increased intracellular glutathione, 
decreased cellular accumulation of drug [1] or increased DNA repair (Fig. 6). Rather, 
their resistance is dependent on a rapid cell cycle progression after drug treatment. 
The regrowth resistance arrest is the same in all cells, the resistant cell lines quickly 
exit this cell cycle arrest despite the presence of DNA damage and continue to cycle. 
Therefore the resistant cells have a decrease in DNA repair in response to platinum 
drug treatment, not because of a downregulation of a DNA repair pathway but 
because of the reduced time in cell cycle arrest where the repair occurs.  
 
The cell cycle associated changes in DNA repair proteins may also be contributing to 
the genomic instability of the cells which will increase the mutagenic potential of the 
cells in response to further drug treatment. Decreases in ERCC1 [40,41] and increases 
in RAD51 [42] have also been associated with increased genomic instability which 
correlate with the large amount of chromosomal aberrations found in the resistant cell 
lines [2] 
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The normal exist from the cell cycle arrest after the successful completion of DNA 
repair is termed checkpoint recovery. Normal checkpoint recovery in the H69 parental 
cells is the 3 week growth arrest (Fig. 2D). Checkpoint adaptation is related to 
checkpoint recovery and promotes cell cycle re-entry even when unrepairable DNA 
damage is present [43]. Checkpoint adaptation has been well characterised in yeast 
cells but more recently has been shown to also occur in human cells in response to 
ionising radiation [44]. The H69CIS200 and H69OX400 cells appear to have the 
checkpoint adaptation phenotype, the cell cycle continuing despite the presence of 
DNA damage. The H69OX400 cells exit the cell cycle arrest faster than the 
H69CIS200 cells and this correlates with the greater amount of chromosomal 
aberrations in the H69OX400 cell line [2]. This suggests that resistance is largely 
dependent on the speed at which the cell cycle arrest can be overcome. The 
H69OX400 have the more ‘aggressive’ phenotype and this correlates with their cross 
resistance to ionising radiation (Fig. 6D). The MTT toxicity assay is a 5-day assay, it 
is likely that the H69CIS200 cells are more radiation resistant than the parental H69 
cells, but at this time point they are both in cell cycle arrest and appear the same. 
 
Conclusions 
 
Resistance in the H69CIS200 and H69OX400 cells is not associated with an increase 
in DNA repair, rather it is associated with the speed of the recovery from the cell 
cycle arrest which may involve modulation of ERCC1 and RAD51B. These cell 
models highlight the multifactorial nature of platinum resistance and that clinical 
markers such as ERCC1 will not identify all types of platinum resistance. 
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Table 1 – Real Time PCR primers 
    Forward Primer Reverse Primer 
Gene Name Accession Pos Tm %GC Sequence Pos Tm %GC Sequence Amplicon
ERCC1 NM001983 841 62.86 55 TCTCCCGGGTGACTGAATGT 970 60.93 55 GGGCATAAGGCCAGATCTTC 129 
MSH2 NM000251 2271 60.66 50 ATCCTCAGGTCTGCAACCAA 2409 60.68 40 CAAACATGCAAAAAGCACCA 138 
RAD51B NM002875 1021 57.84 45 TCGCTGATGAGTTTGGTGTA 1143 60.15 40 ATGCATGGGCGATGATATTT 122 
β Actin NM001101 1642 59.8 45 TTGAATGATGAGCCTTCGTG 1771 58.93 52.2 CTGGTCTCAAGTCAGTGTACAGG 129 
Pos – Position 
 
 
 
 
 
 
 
 






